News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
217,708 Results
Type
Article (22152)
Company Profile (110)
Press Release (195442)
Multimedia
Podcasts (53)
Webinars (4)
Section
Business (51449)
Career Advice (208)
Deals (7748)
Drug Delivery (41)
Drug Development (43666)
Employer Resources (19)
FDA (5089)
Job Trends (4561)
News (103981)
Policy (7927)
Tag
2027 Biotech Bay Standard (2)
2027 Pharm Country Standard (1)
Academia (1287)
Academic (1)
Accelerated approval (21)
Adcomms (15)
Allergies (30)
Alliances (16376)
ALS (109)
Alzheimer's disease (699)
Antibody-drug conjugate (ADC) (278)
Approvals (5233)
Artificial intelligence (165)
Autoimmune disease (119)
Automation (19)
Bankruptcy (50)
Best Places to Work (4141)
BIOSECURE Act (6)
Biosimilars (86)
Biotechnology (90)
Bladder cancer (106)
Brain cancer (44)
Breast cancer (405)
Cancer (3765)
Cardiovascular disease (120)
Career advice (178)
Career pathing (6)
CAR-T (296)
CDC (4)
Cell therapy (811)
Cervical cancer (23)
Clinical research (36001)
Collaboration (856)
Company closure (3)
Compensation (280)
Complete response letters (24)
COVID-19 (1191)
CRISPR (75)
C-suite (338)
Cystic fibrosis (85)
Data (3591)
Denatured (9)
Depression (25)
Diabetes (165)
Diagnostics (1920)
Digital health (7)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (132)
Drug pricing (31)
Drug shortages (2)
Duchenne muscular dystrophy (112)
Earnings (19139)
Editorial (13)
Employer branding (2)
Employer resources (19)
Events (35034)
Executive appointments (318)
FDA (6393)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (8)
Frontotemporal dementia (13)
Funding (594)
Gene editing (152)
Generative AI (15)
Gene therapy (476)
GLP-1 (231)
Government (1115)
Grass and pollen (1)
Guidances (110)
Healthcare (5519)
HIV (23)
Huntington's disease (18)
IgA nephropathy (47)
Immunology and inflammation (154)
Immuno-oncology (46)
Indications (57)
Infectious disease (1280)
Inflammatory bowel disease (89)
Inflation Reduction Act (4)
Influenza (34)
Intellectual property (94)
Interviews (45)
IPO (4038)
IRA (6)
Job creations (625)
Job search strategy (145)
JPM (33)
Kidney cancer (16)
Labor market (10)
Layoffs (194)
Leadership (4)
Legal (908)
Liver cancer (67)
Longevity (10)
Lung cancer (635)
Lymphoma (372)
Machine learning (21)
Management (5)
Manufacturing (370)
MASH (36)
Medical device (1491)
Medtech (1506)
Mergers & acquisitions (4052)
Metabolic disorders (328)
Multiple sclerosis (108)
NASH (3)
Neurodegenerative disease (151)
Neuropsychiatric disorders (18)
Neuroscience (1220)
Neurotech (1)
NextGen: Class of 2026 (1589)
Non-profit (960)
Now hiring (11)
Obesity (126)
Opinion (86)
Ovarian cancer (135)
Pain (42)
Pancreatic cancer (137)
Parkinson's disease (133)
Partnered (15)
Patents (182)
Patient recruitment (245)
Peanut (14)
People (15132)
Pharmaceutical (16)
Pharmacy benefit managers (1)
Phase 1 (13768)
Phase 2 (16496)
Phase 3 (10457)
Pipeline (2377)
Policy (53)
Postmarket research (751)
Preclinical (6361)
Press Release (57)
Prostate cancer (133)
Psychedelics (15)
Radiopharmaceuticals (134)
Rare diseases (469)
Real estate (1312)
Recruiting (8)
Regulatory (7847)
Reports (20)
Research institute (1287)
Resumes & cover letters (33)
Rett syndrome (14)
RNA editing (9)
RSV (21)
Schizophrenia (29)
Series A (90)
Series B (65)
Service/supplier (2)
Sickle cell disease (104)
Special edition (8)
Spinal muscular atrophy (104)
Sponsored (21)
Startups (1268)
State (1)
Stomach cancer (16)
Supply chain (22)
Tariffs (13)
The Weekly (43)
Vaccines (388)
Venture capital (38)
Weight loss (52)
Women's health (17)
Worklife (2)
Date
Today (22)
Last 7 days (212)
Last 30 days (785)
Last 365 days (12455)
2026 (1141)
2025 (12606)
2024 (14622)
2023 (16308)
2022 (20408)
2021 (21004)
2020 (17768)
2019 (12508)
2018 (9453)
2017 (10478)
2016 (9599)
2015 (11597)
2014 (7930)
2013 (6550)
2012 (6647)
2011 (6517)
2010 (5626)
Location
Africa (147)
Alabama (19)
Alaska (3)
Arizona (55)
Arkansas (2)
Asia (15396)
Australia (2963)
California (4603)
Canada (1063)
China (662)
Colorado (133)
Connecticut (130)
Delaware (178)
Europe (32674)
Florida (526)
Georgia (99)
Hawaii (2)
Idaho (21)
Illinois (261)
India (16)
Indiana (77)
Iowa (14)
Japan (238)
Kansas (21)
Kentucky (8)
Louisiana (4)
Maine (55)
Maryland (531)
Massachusetts (3787)
Michigan (63)
Minnesota (132)
Mississippi (1)
Missouri (23)
Montana (10)
Nebraska (6)
Nevada (42)
New Hampshire (12)
New Jersey (1275)
New Mexico (15)
New York (1295)
North Carolina (476)
North Dakota (9)
Northern California (2294)
Ohio (130)
Oklahoma (8)
Oregon (7)
Pennsylvania (920)
Puerto Rico (5)
Rhode Island (19)
South America (221)
South Carolina (4)
Southern California (1759)
Tennessee (32)
Texas (884)
United States (16011)
Utah (110)
Virginia (85)
Washington D.C. (14)
Washington State (489)
Wisconsin (37)
217,708 Results for "cell microsystems.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Stem Cell Specialist PrimeGen Takes SPAC Track to Nasdaq
The SPAC agreement values PrimeGen US at $1.5 billion in equity and gives it capital to advance its pre-clinical triple-activated mesenchymal stem cell pipeline into the clinic.
February 5, 2026
·
1 min read
·
Tristan Manalac
China
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
AstraZeneca has risen as one of pharma’s most prolific investors in China, including a $630 million pledge last week for full rights to AbelZeta’s cell therapy for cancer.
January 29, 2026
·
1 min read
·
Tristan Manalac
Cell therapy
After Cell Therapy Retreat, Novo Offloads Technologies in Deepened Aspect Pact
Novo Nordisk pulled back from cell therapies last October, scrapping development of a type 1 diabetes therapy and laying off most employees working on this modality.
January 21, 2026
·
2 min read
·
Tristan Manalac
Cell Therapy
6 Companies Hanging On in Cell Therapy
As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, these players are sticking around to take the modality as far as it can go.
December 1, 2025
·
9 min read
·
Tristan Manalac
Opinion
Cell and Gene Therapy Will Transform Lives—If We Let It
Mixed headlines have plagued the cell and gene therapy space of late. We believe that a renewed case of optimism is not only warranted but essential if these therapies are to reach their full potential.
November 24, 2025
·
8 min read
·
Tim Hunt
Cell therapy
Galapagos Exits Cell Therapy, Cuts 365 Employees
Galapagos at the start of the year had planned to split into two businesses, with one resulting entity focused on cell therapies. The biotech nixed these plans a few months later, instead choosing to put up for sale multiple cell therapy assets.
October 21, 2025
·
2 min read
·
Tristan Manalac
China
Recently Launched Third Arc Turns to China for Cancer T Cell Engagers
The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to disclose priority indications.
November 13, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion
Cellares, which last year became the first company to receive the FDA’s new advanced manufacturing technology designation, expects to support clinical production this year and offer commercial-scale manufacturing services in 2027.
January 28, 2026
·
2 min read
·
Nick Paul Taylor
Cell therapy
How Takeda Built Its Cell Therapy Portfolio, Only To Walk Away
Takeda wanted to create something new in the cell therapy world by combining the technology with T cell engagers. A series of acquisitions in 2021 started the process.
October 8, 2025
·
2 min read
·
Annalee Armstrong
Layoffs
Novo Retreats From Cell Therapy, Axes Hundreds as Restructuring Rolls On
Novo had around 250 employees working on cell therapies, all of whom will be laid off, though a spokesperson declined to reveal which offices and locations will be affected.
October 13, 2025
·
2 min read
·
Tristan Manalac
1 of 21,771
Next
